Improving protective immunity induced by DNA-based immunization: Priming with antigen and GM-CSF-encoding plasmid DNA and boosting with antigen-expressing recombinant poxvirus

被引:102
作者
Sedegah, M
Weiss, W
Sacci, JB
Charoenvit, Y
Hedstrom, R
Gowda, K
Majam, VF
Tine, J
Kumar, S
Hobart, P
Hoffman, SL
机构
[1] USN, Med Res Ctr, Malaria Program, Silver Spring, MD 20910 USA
[2] Univ Maryland, Sch Med, Dept Microbiol, Baltimore, MD 21201 USA
[3] Virogenet Corp, Troy, NY 12180 USA
[4] Johns Hopkins Univ, Dept Mol Microbiol & Immunol, Baltimore, MD USA
[5] Vical Inc, San Diego, CA 92121 USA
关键词
D O I
10.4049/jimmunol.164.11.5905
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Intramuscular immunization with a naked DNA plasmid expressing the Plasmodium yoelii circumsporozoite protein (pPyCSP) protects mice against challenge with P. yoelii sporozoites, This protection can be improved either by coadministration of a plasmid expressing murine GM-CSF (pGMCSF) or by boosting with recombinant poxvirus expressing the PyCSP, We now report that combining these two strategies, by first mixing the priming dose of pPyCSP with pGMCSF and then boosting with recombinant virus, can substantially increase vaccine effectiveness. Not only were immune responses and protection improved but the pPyCSP dose could be lowered from 100 mu g to 1 mu g with little loss of immunogenicity after boost with recombinant poxvirus, Comparing mice primed by the 1-mu g doses of pPyCSP plus 1 mu g pGMCSF with mice primed by 1-mu g doses of pPyCSP alone, the former were better protected (60% vs 0) and had higher concentrations of Abs (titers of 163, 840 vs 5, 120 by indirect fluorescent Ab test against sporozoites), more ex vivo CTL activity (25% vs 7% specific lysis), and more IFN-gamma-secreting cells by enzyme-linked immunospot assay (1460 vs 280 IFN-gamma spot-forming cells/10(6) cells). Priming with plasmid vaccine plus pGMCSF and boosting with recombinant poxviruses strongly improves the immunogenicity and protective efficacy of DNA vaccination and allows for significant reduction of dose.
引用
收藏
页码:5905 / 5912
页数:8
相关论文
共 33 条
[1]   PLASMODIUM-YOELII - 17-KDA HEPATIC AND ERYTHROCYTIC STAGE PROTEIN IS THE TARGET OF AN INHIBITORY MONOCLONAL-ANTIBODY [J].
CHAROENVIT, Y ;
MELLOUK, S ;
SEDEGAH, M ;
TOYOSHIMA, T ;
LEEF, MF ;
DELAVEGA, P ;
BEAUDOIN, RL ;
AIKAWA, M ;
FALLARME, V ;
HOFFMAN, SL .
EXPERIMENTAL PARASITOLOGY, 1995, 80 (03) :419-429
[2]  
CHAROENVIT Y, 1991, J IMMUNOL, V146, P1020
[3]  
Doolan DL, 1999, J IMMUNOL, V163, P884
[4]   Circumventing genetic restriction of protection against malaria with multigene DNA immunization: CD8(+) T cell-, interferon gamma-, and nitric oxide-dependent immunity [J].
Doolan, DL ;
Sedegah, M ;
Hedstrom, RC ;
Hobart, P ;
Charoenvit, Y ;
Hoffman, SL .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (04) :1739-1746
[5]   EFFECTS OF LOW-DOSES OF RECOMBINANT HUMAN GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR (GM-CSF) IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES [J].
ESTEY, EH ;
KURZROCK, R ;
TALPAZ, M ;
MCCREDIE, KB ;
OBRIEN, S ;
KANTARJIAN, HM ;
KEATING, MJ ;
DEISSEROTH, AB ;
GUTTERMAN, JU .
BRITISH JOURNAL OF HAEMATOLOGY, 1991, 77 (03) :291-295
[6]   SPOROZOITE VACCINE INDUCES GENETICALLY RESTRICTED T-CELL ELIMINATION OF MALARIA FROM HEPATOCYTES [J].
HOFFMAN, SL ;
ISENBARGER, D ;
LONG, GW ;
SEDEGAH, M ;
SZARFMAN, A ;
WATERS, L ;
HOLLINGDALE, MR ;
VANDERMEIDE, PH ;
FINBLOOM, DS ;
BALLOU, WR .
SCIENCE, 1989, 244 (4908) :1078-1081
[7]  
HOFFMAN SL, 1996, MULARIA VACCINE DEV, pCH3
[8]   Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors [J].
Irvine, KR ;
Chamberlain, RS ;
Shulman, EP ;
Surman, DR ;
Rosenberg, SA ;
Restifo, NP .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (21) :1595-1601
[9]  
KUZROCK R, 1992, AM J MED, V933, P41
[10]  
LEONG KH, 1995, VACCINES, P327